Work

rhIL-1RA increase Gemcitabine chemosensitivity by inhibiting NF-κB Activation from IL1 Receptor Antagonist Inhibits Pancreatic Cancer Growth by Abrogating NF-κB Activation

Year: 2023

Type: other

Abstract: We found that rhIL-1RA inhibits IL-1 receptor activation and NF-κB activity. Furthermore, in PDAC cells treated with or without gemcitabine, rhIL-1RA significantly decreases proliferation, migration, invasion, and tumor burden in orthotopic nude mouse model (gemcitabine plus rhIL-1RA vs. control, P=0.014). Thus, these results suggest that IL-1RA can reduce tumor growth by inhibiting IL-1a -induced NF-kB activity; the result also suggests that IL-R is a potential surrogate therapeutic target for mutant Kras and activated NF-kB in treatment of PDAC.

DOI: 10.1158/1078-0432.22459047.v1

Authors: Zhuonan Zhuang, Huai-Qiang Ju, Mitzi Aguilar, Takashi Gocho, Hao Li, Tomonori Iida, Harold Lee, Xiaoqiang Fan, Haijun Zhou, Jianhua Ling, Zhongkui Li, Jie Fu, Min Wu, Min Li, Davide Melisi, Yoichiro Iwakura, Kesen Xu, Jason B. Fleming, Paul J. Chiao

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4361918240

Cites:

Cited by:

Related to: 10